United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are donating doses of their COVID-19 vaccine to athletes participating in this summer's Olympic and Paralympic Games in Tokyo. What Happened: The pharmaceutical companies have signed a Memorandum of Understanding with the International Olympic Committee (IOC) to facilitate the vaccinations in conjunction with the National Olympic Committees that are sending athletes to the quadrennial events.

Pfizer And BioNTech Donate COVID-19 Vaccine To Tokyo Olympians

Moderna

The US has backed a proposal first put forward by India and South Africa for a temporary waiver on COVID-19 vaccine patents. “The administration believes strongly in intellectual property protections, but in service of ending this pandemic, supports the waiver of those protections for COVID-19 vaccines,” said Ambassador Katherine Tai.

Moderna, Pfizer drop after US backs proposal to lift patent protection for COVID-19 vaccines to boost supply

Mizuho Securities says the pharma giant needs its pipeline to deliver for investors to gain more comfort with Pfizer's outlook.

The Ratings Game: Pfizer beat earnings but here's why this analyst downgraded the stock to neutral

Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) had a double dose of good news regarding their COVID-19 vaccines. Moderna said that its tweaked jab was successful in neutralising the South African and Brazilian variants of the virus in laboratory trials.

Coronavirus: Moderna says tweaked vaccine works against variants, two BioNTech/Pfizer doses give 95% protection

Pfizer Inc. and German partner BioNTech SE said Thursday they have signed a memorandum of understanding with the International Olympic Committee to donate their COVID-19 vaccine to help vaccinate athletes participating in this year's Olympic and Paralympic Games Tokyo 2020, which are scheduled to begin on July 23, 2021. Under the terms of the MOU, the companies will coordinate with the IOC to understand the need for vaccine doses for national delegations.

Pfizer and BioNTech to supply IOC with COVID-19 vaccines for Olympic and Paralympic Games athletes

Johnson & Johnson

Novavax

AstraZeneca

If enacted, such a move would hit the smaller vaccine makers particularly hard.

Biden Administration Supports Patent Waivers for Coronavirus Vaccine

According to real-world data released by South Korea, one dose of COVID-19 vaccines from AstraZeneca Plc (NASDAQ: AZN) and Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) was 86.6% effective in preventing infections among people aged 60 and older, reports Reuters. Data revealed by the Korea Disease Control and Prevention Agency (KDCA) showed the Pfizer/BioNTech shot was 89.7% effective in preventing infection at least two weeks after a first dose was given.

Single Shot Of AstraZeneca, Pfizer COVID-19 Vaccines Provide 87% Protection, South Korea Study Shows: Reuters

Pfizer's Inc (NYSE: PFE) Hospira will recall one lot of each of the injectable hospital anesthetics bupivacaine hydrochloride (HCL) and lidocaine HCL following an investigation revealing that a portion of each lot was mislabeled as the other product. Hospira's assessment of the potential risk to patients concluded that the use of the impacted product is likely to cause adverse events of moderate to high severity.

Pfizer's Hospira To Call Back Hospital Anesthetics Due To Mislabeling

The country's health agency credited the change to Pfizer's March trial data in adolescents.

Canada Approves Use Of Pfizer Covid Vaccine In 12- To 15-Year-Olds

Shares of Pfizer Inc. gained 2.5% in trading on Wednesday after Canadian regulators said they authorized using the company's COVID-19 vaccine for children between the ages of 12 and 15 years old. Pfizer developed the vaccine in partnership with BioNTech SE.

Canada authorizes Pfizer's COVID-19 vaccine for kids between the ages of 12 and 15 years old

The shares of Pfizer Inc. (NYSE: PFE) have received a price target increase from $37 to $40 by Barclays. These are the details.

PFE Stock: $40 Target (Up From $37 By Barclays)

Trial results showing how well Pfizer's coronavirus vaccine works in kids as young as two could be ready for regulators by September, Albert Bourla, Pfizer's CEO said Tuesday. Bourla told reporters and analysts during Pfizer's quarterly earnings call that the company expected to have definitive trial data to submit to the Food and Drug Administration (FDA) for two age groups: two to five years old, and five to 11 years old.

We could find out if Pfizer's COVID-19 vaccine works in kids aged 2 to 11 by September

Probably not, but the study could benefit another vaccine maker.

Should Pfizer and Moderna Be Worried About This New COVID Vaccine Study?

The Pfizer shot was 89.7% effective, and AstraZeneca was 86% effective in preventing infections among people over-60 after a single dose, according to South Korean officials.

AstraZeneca And Pfizer Covid-19 Vaccines More Than 86% Effective After First Dose, South Korean Authorities Say

Pfizer, Inc. (PFE) CEO Albert Bourla on Q1 2021 Results - Earnings Call Transcript

Before the market opened on May 4, Pfizer Inc. ( PFE , Financial) released its earnings results for the first quarter of 2021.

Pfizer: Anticipated Growth at a Fair Value

Pfizer said Tuesday it plans to seek full FDA approval for its Covid-19 vaccine by the end of the month. But Pfizer stock was just below a buy point despite strong earnings.

Pfizer Stock Eyes Breakout On Call For $26 Billion In Covid Vaccine Sales

Pfizer Inc.'s ( PFE , Financial) Covid-19 vaccine is poised to knock AbbVie Inc.'s ( ABBV , Financial) Humira off the top perch and become the best-selling medication in pharmaceutical industry history.

Pfizer Covid Vaccine Set to Become Highest-Selling Medication Ever

Pfizer Inc.'s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug maker's top-selling drug and forging a new path into infectious diseases for the legacy drug maker.

Pfizer's next play: A vaccine maker and pandemic ‘partner' to governments

Benzinga's Stock Wars series matches up two leaders in a major industry sector, with the goal of letting readers decide which company is the better investment. In this week's installment, we take a look at two pharmaceutical giants at the forefront of the COVID-19 vaccine development: AstraZeneca plc (NASDAQ:AZN) and Pfizer Inc. (NYSE:PFE).

Stock Wars: AstraZeneca Vs. Pfizer

Pfizer Inc (NYSE: PFE) has paused enrollment in a pivotal trial of its anti-BCMA bispecific antibody after seeing three cases of peripheral neuropathy in an earlier-stage study. In February, Pfizer took its BCMA bispecific elranatamab, also known as PF-06863135, into a pivotal Phase 2 study on the strength of the 80% overall response rate it saw in 20 patients treated in Phase 1.

Pfizer's BCMA/CD3 Bispecific Candidate Study Derailed Amid Safety Woes

Pfizer (PFE) beats estimates for earnings and sales in the first quarter. It lifts its financial outlook for 2021.

Pfizer (PFE) Q1 Earnings Beat, COVID-19 Vaccine Boosts Sales

Mikael Dolsten, Pfizer's chief scientific officer, said it makes sense to start with those most susceptible to Covid.

Pfizer scientist expects elderly, people with underlying conditions to be first to get Covid booster shots

Pfizer could have another pandemic-related revenue stream as it continues work on its COVID-19 booster shots, which are designed to work against certain variants of the virus.

Pfizer expects $26 billion in 2021 sales from COVID vaccine

Pfizer Inc. (NYSE: PFE) reported Tuesday with forecast-beating first-quarter earnings and upwardly revised its fiscal year 2021 earnings and revenue guidance. Despite the impressive results, an analyst at BofA Securities is staying on the sidelines of the COVID-19 vaccine stock.

News for Pfizer Stock (PFE)